BriaCell reports anti-tumor response in patient treated in Phase 2 study

BriaCell Therapeutics reports dramatic anti-tumor response including complete resolution of temporal lobe breast cancer metastasis in a patient treated in the Phase 2 study of BriaCell’s Bria-IMT plus an immune checkpoint inhibitor regimen. The patient demonstrated an initial partial response at 2 months in the brain lesion with no detectable disease following 8 and 11 months of treatment. The heavily pre-treated patient who had failed 8 prior regimens including ADC therapy, previously demonstrated significant reduction of her “Eye-Bulging” orbital tumor and continues treatment with the Bria-IMT regimen. She has completed 17 cycles of treatment and has been on BriaCell’s Phase 2 study for 12 months. Also noteworthy is a sustained drop in her tumor markers, confirming the imaging results of marked tumor reduction. The right temporal lobe lesion is no longer detectable on the images taken at 8 months and 11 months on the Bria-IMT combination regimen. The orbital lesion has continued to shrink markedly. In addition, her tumor markers remain markedly decreased from her pre-treatment levels.